Claud Grigg
YOU?
Author Swipe
View article: 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)
17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433) Open
Background Despite advances in the treatment of metastatic ccRCC, few patients are cured. Therapies exploiting novel targets are needed. Antigen screening identified ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase family member 3) …
View article: REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens Open
The REnal cancer consortium for Focused Investigation of Novel biomarkers and Expression (REFINE) consortium represents an important initiative in integrating clinical data with molecular sequencing in patients with advanced renal cell car…
View article: Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer Open
Gal-1 and Gal-3 H-score per bladder did not independently predict for RFS or OS. Intra-tumoral Gal-1/Gal-3 heterogeneity complicates the use of Gal-1 and Gal-3 expression as a prognostic biomarker. Future studies should consider the evalua…
View article: Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes
Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes Open
These results support the role for tumor genomic profiling in SCBC and identify multiple potential novel biomarkers and therapeutic targets in this rare disease. Efforts to validate these findings should lead to improved decision-making an…
View article: Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle‑invasive bladder cancer
Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle‑invasive bladder cancer Open
Biomarkers are needed in muscle-invasive bladder cancer (MIBC). We previously reported that high tumor aurora kinase (AURK) A expression identifies patients with MIBC with poor prognosis. Aberrant p53 expression has also been associated wi…
View article: MP30-14 5-ARI USAGE ASSOCIATED WITH MORE ADVANCED PROSTATE CANCER AT DIAGNOSIS
MP30-14 5-ARI USAGE ASSOCIATED WITH MORE ADVANCED PROSTATE CANCER AT DIAGNOSIS Open
You have accessJournal of UrologyProstate Cancer: Detection & Screening III (MP30)1 Sep 2021MP30-14 5-ARI USAGE ASSOCIATED WITH MORE ADVANCED PROSTATE CANCER AT DIAGNOSIS Emily Roebuck, Wei Sha, Caroline Lu, Caroline Miller, Earle F Burges…
View article: MP30-12 RACIAL AND SOCIOECONOMIC DISPARITIES IN MRI-FUSION BIOPSY UTILIZATION FOR THE DETECTION OF PROSTATE CANCER
MP30-12 RACIAL AND SOCIOECONOMIC DISPARITIES IN MRI-FUSION BIOPSY UTILIZATION FOR THE DETECTION OF PROSTATE CANCER Open
You have accessJournal of UrologyProstate Cancer: Detection & Screening III (MP30)1 Sep 2021MP30-12 RACIAL AND SOCIOECONOMIC DISPARITIES IN MRI-FUSION BIOPSY UTILIZATION FOR THE DETECTION OF PROSTATE CANCER Emily Roebuck, Wei Sha, Caroline…
View article: Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients
Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients Open
Differences in the genomic profiles of HG T1 NMIBC tumors exist between those who show durable response to BCG and those who do not. Using pathway analysis, those differences imply upregulation of several interconnected inflammatory pathwa…
View article: Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort
Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort Open
BACKGROUND: Limited stage small cell bladder cancer is curable with multi-modality therapy using external beam radiotherapy or radical cystectomy. The optimal management strategy for this rare disease is still debated, yet few case series …
View article: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? Open
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune…